EQT Strikes A €9.6 Billion Deal For Qiagen
EQT has agreed to acquire Qiagen for €9.6 billion, offering €46.50 per share. The deal is expected to close in mid-2027, pending regulatory approvals and financing. Qiagen's stock rose 0.7% on the news, trading below the offer price due to the long timeline and associated risks.
How this was made
The 30-second read
Why it matters
The announcement triggers modest share price movement but leaves a wide arbitrage spread due to the long closing horizon.
Market read
The deal is a primary M&A event with significant size, creating arbitrage opportunities and sector‑wide attention.
What to watch
Currency risk between euros and dollars and potential antitrust scrutiny in the US could affect the final valuation.
Background
EQT, a Swedish private‑equity firm, is pursuing a €9.6 billion takeover of Qiagen, a molecular diagnostics company listed on NASDAQ as QGEN.
Ticker impact
EQT announced a €9.6 billion acquisition of Qiagen, pausing Qiagen's 2026 outlook and causing a 0.7% rise in its US‑listed shares.
likely pressure as the market prices in completion risk and time discount, keeping the stock below the offer price
Merger‑arbitrage spreads typically remain wide for long‑duration deals; the modest 0.7% move suggests limited immediate upside.
Market effects
The biotech sector may see heightened arbitrage activity as other M&A targets are evaluated against similar long‑duration timelines.
European private‑equity activity is underscored, but limited direct effect on broader markets.
Large‑scale cross‑border M&A adds to global deal flow sentiment but does not shift macro trends.
Counterpoint
If regulatory or financing hurdles arise, the deal could be delayed or renegotiated, potentially pushing Qiagen stock lower.
Key entities
- AcquirerEQT
Swedish private‑equity firm leading the €9.6 billion deal.
- TargetQiagen
Molecular diagnostics company listed as QGEN.
